IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

Results presented at AACR 2023 found that four times as many patients treated with Imfinzi plus chemotherapy before surgery achieved pathologic complete response versus those treated with neoadjuvant... | April 16, 2023

Related Keywords

Canada ,Cambridge ,Cambridgeshire ,United Kingdom ,Florida ,United States ,China ,Houston ,Texas ,Orlando ,Japan ,American ,America ,Johnv Heymach ,Le Chevalier ,Daiichi Sankyo ,Susan Galbraith ,Lung Ambition Alliance ,University Of Texas Md Anderson Cancer Center ,Astrazeneca ,Lungevity Foundation ,Arch Pathol Lab ,American Association For Cancer Research ,World Health Organization ,American Association ,Cancer Research ,Annual Meeting ,Neck Medical Oncology ,Cancer Center ,Executive Vice President ,Stratified Cox ,Thyroid Disorders ,Immune Mediated Nephritis ,Immune Mediated Dermatology ,Stevens Johnson Syndrome ,Prescribing Information ,Medication Guide ,Eighth Edition ,Staging Manual ,South America ,Rare Diseases ,Pathol Lab ,Astrazeneca Plc Stock Exchange ,News ,Information ,Press Release ,Results ,Resented ,It ,Racr ,023 ,Hound ,Hat ,Four ,Times ,Us ,Many ,Patients ,Reated ,Ith ,Imfinzi ,Plus ,Chemotherapy ,Before ,Surgery ,Chieved ,Pathologic ,Omplete ,Response ,Versus ,Whose ,Ith Azn Gb0009895292 ,